Skip to main content

Mesoblast (NASDAQ: MESO) — Company Overview, News & Financial Data

Mesoblast logo
MESO Mesoblast
Mesoblast primary media
Company profile

Mesoblast

About

Explore United States companies

Mesoblast (ASX:MSB), (NASDAQ:MESO) is a biopharmaceutical company focused on developing and commercializing innovative allogeneic cellular medicines to treat severe and life-threatening conditions. The company's products are based on its proprietary mesenchymal lineage cell therapy technology, which aims to provide significant improvements for patients suffering from inflammatory ailments, cardiovascular diseases, and back pain. Mesoblast's pipeline includes several late-stage clinical candidates targeting conditions such as acute graft versus host disease, chronic heart failure, and chronic low back pain. Their objective is to harness the power of cells to regenerate tissues and organs and to provide life-changing treatments for patients who have limited options. Mesoblast is also traded on the Australian Securities Exchange (ASX:MSB), highlighting its global presence and commitment to advancing healthcare through innovative medical research.

Snapshot

Public USOwnership
2004Year founded
83Employees
Melbourne, AustraliaHead office
Loading Map...
Global footprint

Operations

All Locations
Melbourne, AU

Products and/or services of Mesoblast

  • Ryoncil (remestemcel-L) for treating steroid-refractory acute graft versus host disease in children.
  • REVASCOR for advanced chronic heart failure treatment aiming to reduce major adverse cardiovascular events.
  • MPC-150-IM for reducing heart failure-related hospitalizations in patients with left ventricular systolic dysfunction.
  • MPC-25-IC for treating acute myocardial infarction to improve heart function.
  • Remestemcel-L for COVID-19 induced acute respiratory distress syndrome, aiming to improve survival in severely affected patients.
  • MPC-06-ID for treating chronic low back pain due to disc degeneration, focusing on reducing pain and improving function.

Mesoblast executive team

  • Silviu ItescuFounder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
  • Eric A. RoseChief Medical Officer & Executive Director
  • Paul HughesGlobal Head of Corporate Communications & Joint Company Secretary
  • Anthony WhealHead of Human Resources
  • Paul J. SimmonsScientific Advisor to the Chief Executive Officer
  • Geraldine StortonHead of Regulatory Affairs & Quality Management
  • Daniel DevineHead of Special Projects
  • Justin HorstHead of Manufacturing
  • Fiona SeeSenior VP & Head of Translational Research
  • Marcelo SantoroChief Commercial Officer